Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate
Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company’s lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key …
Read more on News-Medical-Net
Loading...
